EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 824 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... September 21, 2023 Black Patients Are More Likely to Die of Cancer—Here’s How One... December 21, 2021 ScottishPower supports vital research into air pollution and cancer November 24, 2022 Load more HOT NEWS Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer Research shows one size doesn’t fit all for cervical screening in... Woman Suffers Seizure And Dies After Making Fatal Error With Her...
